227 related articles for article (PubMed ID: 26142388)
1. Probiotic Saccharomyces cerevisiae strains as biotherapeutic tools: is there room for improvement?
Palma ML; Zamith-Miranda D; Martins FS; Bozza FA; Nimrichter L; Montero-Lomeli M; Marques ET; Douradinha B
Appl Microbiol Biotechnol; 2015 Aug; 99(16):6563-70. PubMed ID: 26142388
[TBL] [Abstract][Full Text] [Related]
2. In vitro screening of probiotic properties of Saccharomyces cerevisiae var. boulardii and food-borne Saccharomyces cerevisiae strains.
van der Aa Kühle A; Skovgaard K; Jespersen L
Int J Food Microbiol; 2005 May; 101(1):29-39. PubMed ID: 15878404
[TBL] [Abstract][Full Text] [Related]
3. Molecular tools for differentiating probiotic and clinical strains of Saccharomyces cerevisiae.
Posteraro B; Sanguinetti M; Romano L; Torelli R; Novarese L; Fadda G
Int J Food Microbiol; 2005 Sep; 103(3):295-304. PubMed ID: 16099314
[TBL] [Abstract][Full Text] [Related]
4. Fungemia following Saccharomyces cerevisiae var. boulardii probiotic treatment in an elderly patient.
Landaburu MF; López Daneri GA; Relloso S; Zarlenga LJ; Vinante MA; Mujica MT
Rev Argent Microbiol; 2020; 52(1):27-30. PubMed ID: 31262611
[TBL] [Abstract][Full Text] [Related]
5. Yeasts as probiotics: Mechanisms, outcomes, and future potential.
Sen S; Mansell TJ
Fungal Genet Biol; 2020 Apr; 137():103333. PubMed ID: 31923554
[TBL] [Abstract][Full Text] [Related]
6. Antioxidant properties and global metabolite screening of the probiotic yeast Saccharomyces cerevisiae var. boulardii.
Datta S; Timson DJ; Annapure US
J Sci Food Agric; 2017 Jul; 97(9):3039-3049. PubMed ID: 27868205
[TBL] [Abstract][Full Text] [Related]
7. Review article: yeast as probiotics -- Saccharomyces boulardii.
Czerucka D; Piche T; Rampal P
Aliment Pharmacol Ther; 2007 Sep; 26(6):767-78. PubMed ID: 17767461
[TBL] [Abstract][Full Text] [Related]
8. Novel insights in genetic transformation of the probiotic yeast Saccharomyces boulardii.
Douradinha B; Reis VC; Rogers MB; Torres FA; Evans JD; Marques ET
Bioengineered; 2014; 5(1):21-9. PubMed ID: 24013355
[TBL] [Abstract][Full Text] [Related]
9. Functional heterologous protein expression by genetically engineered probiotic yeast Saccharomyces boulardii.
Hudson LE; Fasken MB; McDermott CD; McBride SM; Kuiper EG; Guiliano DB; Corbett AH; Lamb TJ
PLoS One; 2014; 9(11):e112660. PubMed ID: 25391025
[TBL] [Abstract][Full Text] [Related]
10. Unique genetic basis of the distinct antibiotic potency of high acetic acid production in the probiotic yeast
Offei B; Vandecruys P; De Graeve S; Foulquié-Moreno MR; Thevelein JM
Genome Res; 2019 Sep; 29(9):1478-1494. PubMed ID: 31467028
[TBL] [Abstract][Full Text] [Related]
11. Transcriptome-wide differences between Saccharomyces cerevisiae and Saccharomyces cerevisiae var. boulardii: Clues on host survival and probiotic activity based on promoter sequence variability.
Pais P; Oliveira J; Almeida V; Yilmaz M; Monteiro PT; Teixeira MC
Genomics; 2021 Mar; 113(2):530-539. PubMed ID: 33482324
[TBL] [Abstract][Full Text] [Related]
12. Genotypic and physiological characterization of Saccharomyces boulardii, the probiotic strain of Saccharomyces cerevisiae.
Edwards-Ingram L; Gitsham P; Burton N; Warhurst G; Clarke I; Hoyle D; Oliver SG; Stateva L
Appl Environ Microbiol; 2007 Apr; 73(8):2458-67. PubMed ID: 17293506
[TBL] [Abstract][Full Text] [Related]
13. Application of Saccharomyces cerevisiae var. boulardii in food processing: a review.
Lazo-Vélez MA; Serna-Saldívar SO; Rosales-Medina MF; Tinoco-Alvear M; Briones-García M
J Appl Microbiol; 2018 Oct; 125(4):943-951. PubMed ID: 29961970
[TBL] [Abstract][Full Text] [Related]
14. [Saccharomyces cerevisiae fungemia in an elderly patient following probiotic treatment].
Eren Z; Gurol Y; Sonmezoglu M; Eren HS; Celik G; Kantarci G
Mikrobiyol Bul; 2014 Apr; 48(2):351-5. PubMed ID: 24819274
[TBL] [Abstract][Full Text] [Related]
15. Saccharomyces cerevisiae decreases inflammatory responses induced by F4+ enterotoxigenic Escherichia coli in porcine intestinal epithelial cells.
Zanello G; Meurens F; Berri M; Chevaleyre C; Melo S; Auclair E; Salmon H
Vet Immunol Immunopathol; 2011 May; 141(1-2):133-8. PubMed ID: 21354630
[TBL] [Abstract][Full Text] [Related]
16.
Pais P; Almeida V; Yılmaz M; Teixeira MC
J Fungi (Basel); 2020 Jun; 6(2):. PubMed ID: 32512834
[No Abstract] [Full Text] [Related]
17. Clinical indications for probiotics: an overview.
Goldin BR; Gorbach SL
Clin Infect Dis; 2008 Feb; 46 Suppl 2():S96-100; discussion S144-51. PubMed ID: 18181732
[TBL] [Abstract][Full Text] [Related]
18. Saccharomyces boulardii: a summary of the evidence for gastroenterology clinical practice in adults and children.
Berni Canani R; Cucchiara S; Cuomo R; Pace F; Papale F
Eur Rev Med Pharmacol Sci; 2011 Jul; 15(7):809-22. PubMed ID: 21780551
[TBL] [Abstract][Full Text] [Related]
19. A new therapeutic association to manage relapsing experimental colitis: Doxycycline plus Saccharomyces boulardii.
Garrido-Mesa J; Algieri F; Rodriguez-Nogales A; Utrilla MP; Rodriguez-Cabezas ME; Zarzuelo A; Ocete MA; Garrido-Mesa N; Galvez J
Pharmacol Res; 2015 Jul; 97():48-63. PubMed ID: 25917208
[TBL] [Abstract][Full Text] [Related]
20. Effects of
West C; Stanisz AM; Wong A; Kunze WA
World J Gastroenterol; 2016 Dec; 22(48):10532-10544. PubMed ID: 28082805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
